AVT06 has been approved for marketing as an aflibercept biosimilar in the United Kingdom, Japan and the 30 countries of the European Economic Area, which includes all 27 member states of the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback